>EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products.(http://www.eusapharma.com/)

 

>Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of patients by building, developing, and commercializing a portfolio of oncology products. (http://www.cytogen.com)

---

>AGREEMENT AND PLAN OF MERGE 

 

>Press Release:

 

>Consideration:

Outstanding shares of the Cytogen will be converted into $0.62 per share in cash

 

>Expected Closed:

2Q 2008

 

>Termination fee:

Cytogen to pay a fee equal to 5% of the merger consideration and up to $0.5 million in reimbursements of expenses.

 

>Notes:

> 3/14/2008 Cytogen Reports Fourth Quarter and Full Year 2007 Financial Results